瑞博生物技术股份有限公司 focuses on the research and development of small nucleic acid drug delivery technologies and chemical modifications. It has established a drug development platform that integrates various technologies for small nucleic acids, supporting the lifecycle from early research to industrialization.

瑞博生物技术股份有限公司

Suzhou Ribo Life Science Co., Ltd | 356 followers on LinkedIn. Dedicated to Innovative Oligonucleotide Therapeutics to Improve Human Health and Wellbeing | Established in 2007, Suzhou Ribo Life Science Co., Ltd. (Ribo) is a clinical stage company devoted to the development of innovative RNAi technologies  and oligonucleotide therapeutics as an effort to address unmet clinical needs in the world with the tools, capacity and RNA therapeutics that we build up in China. Fueled by our mission to make China&#39;s oligonucleotide therapeutics serve the world, we seek.

CHINA HEALTHCARE BUSINESS DEVELOPMENT ASSOCIATION

Sam Ma

Suzhou Ribo Life Science Ltd. - VP

Shan Gao

Vice President

Hong Yu

Finance Controller at Suzhou Ribo Life Science Co.,Ltd

Jane Gu

Suzhou Ribo Life Science Co., Ltd

Great mielstone to step into rare disease!

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9

We are very pleased to announce this strategic collaboration, leveraging our innovative siRNA technology platform to deliver next-generation treatments for patients with liver diseases.

RIBO

COM:RIBOLIA

瑞博生物技术股份有限公司